Mindray Completes Acquisition of HyTest

Published: 23.09.2021
30 Aug, 2021
HyTest is Donating Time and Joy to a Lonely Senior Citizen

The loneliness of elderly people is a problem in Finland, the homecountry of HyTest. We wanted to be a part of the solution. That is why HyTest is now collaborating with a Finnish company called Gubbe.

Read more
16 Aug, 2021
Meet HyTest Team at AACC 2021

We will be attending the 2021 AACC Annual Meeting & Clinical Lab Expo. The exhibition will be on August 26 - 30 in Atlanta.


Read more
07 Jul, 2021
New Feline SAA Antibodies

Serum amyloid A is the only major acute phase protein in cats. It can be used as a sensitive marker of inflammation.

Read more
17 May, 2021
HyTest to be Acquired by Mindray

HyTest's current majority owner, Summa Equity, has signed a definitive agreement to sell HyTest to Mindray, a leading global medical technology company. HyTest has been partnering with Mindray already for over ten years. In going forward, HyTest is committed to serving all of its customers and will continue to provide high-quality diagnostic raw materials as before.

Read more
28 Apr, 2021
New! SARS-CoV-2 Nucleoprotein Polyclonal Antibodies Help to Detect Variants

Polyclonal SARS-CoV-2 NP antibodies provide an excellent addition to the mix of antibodies to select for COVID-19 Antigen test development.

Read more
27 Apr, 2021
D-dimer – Prognostic and Severity Marker for COVID-19 Diagnostics

Elevated levels of D-dimer have been found in the blood of patients with pulmonary embolism (PE) and deep vein thrombosis (DVT). The elevated level of D-dimer in blood is believed to be a reliable marker of pathological coagulation. During the COVID-19 pandemic D-dimer has been commonly elevated in patients with SARS-CoV-2. It has been shown to correlate with disease severity and to be a reliable prognostic marker for hospitalization and mortality assessment in patients admitted for COVID-19.

Read more
21 Apr, 2021
HyTest Webinar - Biomarkers of Inflammation: Interleukin-6 and Beyond

 By watching this webinar, you will learn about:
- inflammation process and its clinical importance
- the clinical value of Interleukin-6 and other inflammation markers, as well as the benefits and limitations of these markers for diagnostics
- the role of Interleukin-6 in distinguishing the severity and prognosis of COVID-19

Read more
31 Mar, 2021
New Antibodies to Interleukin-6 (IL-6)

We have now developed 7 new MAb pairs to IL-6 that are suitable for high sensitivity IL-6 assay development.

Read more
30 Mar, 2021
New Recombinant COVID-19 Related Antigens

Angiotensin converting enzyme 2 (ACE2) and SARS-CoV-2 Nucleoprotein fragment N47-A173 samples available

Read more
29 Mar, 2021
EFLM Cardiac Marker Award - Sponsored by HyTest

Call for nominations! We are delighted to let you know that we are sponsoring the EFLM-HyTest Cardiac Marker Award for remarkable scientific work in the field of cardiovascular diseases.

Read more
24 Feb, 2021
New Pair Recommendations for the Development of High-Sensitivity Troponin I Assays

Early diagnosis of acute myocardial infarction (AMI) as a life-threatening disorder is important for immediate evidence-based therapy. The cardiac troponin I (cTnI) is a gold standard and diagnostic cornerstone in the clinical assessment of AMI. It offers accurate and rapid AMI rule outs.

Read more
24 Feb, 2021
Meet HyTest China Team at CACLP Expo and Satellite Conference

Meet HyTest China team at the 18th China Association of Clinical Laboratory Practice Expo held at Chongqing International Expo Center, on 28-30 March.

Read more
28 Jan, 2021
COVID-19 Antibodies Update - New R&D Samples Available

New R&D samples available:
- Polyclonal anti-SARS-CoV-2 Nucleoprotein
- New anti-SARS-CoV-2 RBD clones

Read more
28 Jan, 2021
New Appointments in the Sales Team

We are delighted to introduce our latest team member, Outi Vilamo and Netta Keinänen was appointed as the new Sales and Marketing Director from the beginning of January 2021

Read more
28 Jan, 2021
Listen our Awarded AACC Poster

Our scientists presented an awarded poster at the virtual AACC 2020:
“Diverse Short-Term Natriuretic Response in Acute Decompensated Heart Failure Patients Undergoing Entresto™ Treatment"

Read more
28 Dec, 2020
HyTest Group Welcomes Juhana Rauramo as its New CEO

Juhana Rauramo will become the new CEO of HyTest Group Oy with effect from January 1, 2021. Juhana has proven to be a very valuable person for HyTest and he has agreed to take on a more extensive role regarding the management of the company. Meanwhile, Maria Severina, the Founder and CEO of the company for the last 26 years will continue as a board member for HyTest Group Oy and she will be available as a consultant to the company.
Juhana has been the CCO of HyTest and a member of the management team since September 2019.

Read more
21 Dec, 2020
Season's Greetings 2020

In this exceptional year we must make exceptional actions. Check our Season's Greetings video to you:

Read more
10 Dec, 2020
Meet HyTest Team at Virtual AACC Expo

Connect with our representative during the AACC virtual expo, taking place December 14–17. Schedule a meeting at our booth through the virtual platform or contact us already now and agree a meeting.

Our new Sales Manager Outi Vilamo will be also waiting to meet you there.


Read more
08 Dec, 2020
Update on COVID-19 Antibodies

We are pleased to let you know that we now have the first four anti-nucleoprotein antibodies available in their final forms.

Read more

Sign up to our newsletter

And be informed about new products and scientific findings

Thank you for your subscription!